News ArticleAdding bevacizumab to standard first-line carboplatin and paclitaxel chemotherapy therapy against ovarian cancer prolonged progression-free survival in two separate, complementary, phase III clinical trials reported in the Dec. 29 issue of the New England Journal of Medicine.Bevacizumab (Avastin) did not interfere with chemotherapy. Although it raised the rate of toxic effects, this did not impair patients’ quality of life in either study. Both trials received industry support.The GOG...